“The use of QMENTA's platform has allowed us to remain flexible during the planning and activation stage of our Alzheimer's disease clinical trial. The scalability and ease of use of their service has allowed us to grow and adapt the study as needed. QMENTA streamlines the standardization, collection, and storage elements of multi-center imaging, taking on responsibilities that are typically the job of MRI technicians and sponsors. QMENTA has reduced the costs of MR imaging collection and storage in the trial by approximately 50% and has reduced site burden by an estimated 75%. Coupling these savings with streamlined back-end analysis tools has been a tremendous help keeping our trial on budget and on time.”

Kent LeslieCEO of Amylyx Pharmaceuticals

“Our partnership with QMENTA enables efficient and immediate access to our quantitative imaging solutions to those involved in clinical trials and research. It is exciting to be part of QMENTA’s neuro-centric platform and helping advance the understanding of neurological disorders.”

Michael SchmaindaPresident & CEO at Imaging Biometrics

“QMENTA solutions fill a significant unmet need for all researchers and clinicians working with imaging. In imaging studies from patients with Multiple Sclerosis, their solution for obtaining the brain connectome, quantifying brain damage and related it with clinical scores is outstanding, and it is going to solve many clinically relevant questions. In addition, I envision QMENTA solutions are going to be extremely useful in clinical practice and for conducting clinical trials developing new drugs for MS.”

Pablo Villoslada Diaz, MD, PhDSenior Researcher IDIBAPS; Founder & Scientific Advisor Bionure; Adjunct Professor UCSF

“My lab has been working with QMENTA primarily for developing a new treatment for Down syndrome using MRI at pre-clinical validation with mice models. Their platform is necessary to accelerate the discoveries in the field and will have a very large impact. The platform that they provide is a great tool for data management and processing. It is very flexible and efficient, providing quick answers to our research questions. We feel very comfortable and satisfied to work with the team, given their scientific approach that turns their product as a partner, rather than just a tool.”

Mara Dierssen, MD, PhDSystems Biology Program at a large center for genomics investigations

“This technology changes dramatically the way we understand these diseases, and help us determine which parts of the brain are not working properly. We are using these quantification tools to detect easier which brain regions are damaged and help us find better and personalized treatments for our patients.”

Angels García-Cazorla, MD, PhDPrincipal Investigator at Hospital Sant Joan de Déu